The global influenza treatment market size accounted for $861.50 million in 2018 and is expected to reach $1,225.20 million by 2026, registering a CAGR of 4.5% from 2019 to 2026.
Influenza is commonly known as flu and is a contagious respiratory infection, which is caused by influenza viruses. Furthermore, the virus is classified into Type A, B, C, and D. The most common types of influenza virus responsible for seasonal flu each year are Type A and B. Moreover, these viruses attack the respiratory system of an individual and are transmitted to other individuals by direct contact or inhalation of virus-laden aerosols. The major symptoms of the disease include sore throat, fatigue, muscle ache, vomiting, and diarrhea. In addition, it can worsen long-term medical conditions like congestive heart failure, asthma, or diabetes which, in turn, can lead to serious complications. Therefore, influenza infections are treated in time using various types of anti-viral drugs such as Peramivir and Zanamivir.
The major factor that contributes to the growth of the influenza treatment market includes a rise in incidences of influenza across the globe. Furthermore, other factors such as a surge in healthcare expenditure, and a rise in R&D investments related to anti-viral drugs further boost the influenza treatment market growth. For instance, in 2018, F. Hoffmann-La Roche AG launched Xofluza (Baloxavir Marboxil) for the treatment of influenza. Furthermore, Xofluza is the first new flu medicine with a novel proposed mechanism of action. Therefore, this leads to the availability of better treatment options for patients. However, the adoption of influenza vaccines hampers the growth of the influenza treatment market. Conversely, high growth potential exhibited by developing economies such as India and China having a large population base and notable epidemiology of influenza infection is expected to offer lucrative opportunities for the market during the forecast period.
INFLUENZA TREATMENT MARKET SEGMENTATION
The influenza treatment market size is studied on the basis of product type, distribution channel, and region to provide a detailed assessment. On the basis of product type, it is segmented into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and others. By distribution channel, it is bifurcated into retail pharmacy, hospital pharmacy, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and Rest of LAMEA).
Segment Review
By product, the market is classified into is segmented into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and others. The other segment acquired the largest share of the influenza treatment market in 2018. Furthermore, the segment is also anticipated to exhibit the fastest growth during the forecast period. The growth of this segment is attributable to a surge in the prevalence of influenza virus infection across the globe. Furthermore, a rise in awareness related to early diagnosis of the infection for better treatment is another major reason that contributes to the growth of the market.
By distribution channel, the influenza treatment market is divided into retail pharmacy, hospital pharmacy, and others. The retail pharmacy segment occupied the largest market share in 2018, owing to factors such as a rise in the number of retail pharmacies across the globe. In addition, other factors such as the rise in awareness related to the use of influenza drugs are another major factor that contributes to the growth of the market. The other factors which boost the growth of the market include a surge in the number of retail pharmacies across the globe which leads to the easy availability of influenza drugs. On the contrary, the other segment is expected to witness the fastest growth rate during the forecast period due to a surge in the use of the internet across the globe, which allows consumers to buy drugs online.
By region, North America accounted for the major influenza treatment market share in 2018 and is expected to continue this trend, owing to the easy availability of influenza treatment. Moreover, surge in incidences of influenza infection is another major reason that contributes to the growth of this market. Moreover, a surge in the awareness of the early diagnosis of the medical condition for better treatment is another major factor that contributes to the growth of the market. However, Asia-Pacific is estimated to register the fastest growth rate during the forecast period, owing to an increase in awareness regarding the use of influenza drugs for the treatment of infection.
Moreover, an increase in healthcare expenditure and a surge in awards related to the use of influenza treatment is another major factor that boosts the growth of the influenza treatment market. In addition, the presence of key players in these regions also fuels the growth of the influenza treatment in Asia-Pacific. In addition, the constantly evolving life science industry in Asia-Pacific drives the growth of the market in developing economies such as India, China, and Malaysia.
The global influenza treatment market is highly competitive and prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include AstraZeneca Plc, BioCryst Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Mylan N.V, Natco Pharma Limited, Novartis AG, Sanofi, and Teva Pharmaceutical Industries Limited.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the global influenza treatment market trends from 2018 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The influenza treatment market forecast is studied from 2018 to 2026.
- The market size and estimations are based on a comprehensive analysis of key developments in the influenza treatment industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the influenza treatment market
Key Market Segments
By Product type
- Peramivir
- Zanamivir
- Oseltamivir Phosphate
- Baloxavir Marboxil
- Others
By Distribution channel
- Retail Pharmacy
- Hospital Pharmacy
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Table of Contents
Executive Summary
According to this report titled, 'Influenza Treatment Market by Product Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2018-2026,' the global influenza treatment market size was valued at $862 million in 2018 and is expected to reach $1.2 billion by 2026, registering a CAGR of 4.5% from 2019 to 2026.
Influenza drugs are defined as the medicines which are employed for the treatment of patients suffering from influenza. Influenza is a viral infection caused by influenza viruses such as type A, type, and type B. Furthermore, the virus is more serious in some groups of people such as pregnant women, older people, young children, and people suffering from chronic diseases. Moreover, the infection manifests a wide range of clinical symptoms such as headache, muscle aches, high fever, and vomiting. In addition, severe cases of influenza can also lead to fatalities. Therefore, treatment of the condition is necessary and requires the use of anti-viral drugs such as Peramivir, Zanamivir, Oseltamivir Phosphate, and Baloxavir Marboxil.
Rise in incidences of influenza across the globe is the major factor that contributes to the growth of the influenza treatment market. Furthermore, other factors such as surge in healthcare expenditure and a rise in R&D investments related to ant-viral drugs boost the influenza treatment market growth. For instance, in 2018, F. Hoffmann-La Roche AG launched Xofluza (Baloxavir Marboxil) for the treatment of influenza. Furthermore, Xofluza is the first new flu medicine with a novel proposed mechanism of action. Therefore, this leads to availability of better treatment option for the patients. However, adoption of influenza vaccines hampers the growth of the influenza treatment market. Conversely, high growth potential exhibited by developing economies due to a surge in awareness related to early detection and treatment of influenza is expected to offer lucrative opportunities for the market during the forecast period.
The influenza treatment market size is studied on the basis of product type, distribution channel, and region to provide a detailed assessment. On the basis of product type, it is segmented into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and others. By distribution channel, it is bifurcated into retail pharmacy, hospital pharmacy, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and Rest of LAMEA).
By product, the market is classified into is segmented into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and others. The other segments acquired the largest share of the influenza treatment market in 2018. Furthermore, the segment is also anticipated to exhibit fastest growth during the forecast period. The growth of this segment is attributable to surge in The prevalence of influenza virus infection across the globe. Furthermore, a rise in awareness related to early diagnosis of the infection for better treatment is another major reason that contributes to the growth of the market.
By distribution channel, the influenza treatment market is divided into retail pharmacy, hospital pharmacy, and others. The retail pharmacy segment occupied the largest market share in 2018, owing to factors such as a rise in the number of retail pharmacies across the globe. In addition, other factors such as rise in awareness related to use of influenza drugs is another major factor that contributes to the growth of the market. The other factors which boost the growth of the market include a surge in the number of retail pharmacies across the globe which leads to the easy availability of influenza drugs. On the contrary, the other segment is expected to witness the fastest growth rate during the forecast period due to a surge in the use of the internet across the globe, which allows consumers to buy drugs online.
By region, North America accounted for the major influenza treatment market share in 2018, and is expected to continue this trend, owing to easy availability of influenza treatment. Moreover, surge in incidences of influenza infection is another major reason that contributes to the growth of this market. However, Asia-Pacific is estimated to register the fastest growth rate during the forecast period, owing to an increase in awareness regarding the use of influenza drugs for the treatment of infection. The constantly evolving life science industry in Asia-Pacific drives the growth of the market in developing economies such as India, China, and Malaysia. . As the constant development leads to surge in awareness related to the use of influenza treatment.
KEY FINDINGS OF THE STUDY
- Oseltamivir phosphate occupied more than two-fifth share of the global influenza treatment market in 2018.
- The others segment in distribution channel pharmacy segment is anticipated to grow with the highest CAGR throughout the forecast period.
- The others segment in product type accounted for more than two-fifth share of the market in 2018.
- Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
Companies Mentioned
- AstraZeneca Plc
- BioCryst Pharmaceuticals Inc.
- Daiichi Sankyo Company
- Limited
- F. Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Mylan N.V
- Natco Pharma Limited
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Limited
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
